Valeant

Valeant acquires Visudyne from QLT

Tuesday, September 25, 2012 10:57 AM

Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT.

More... »

Valeant to acquire Medicis, strengthen dermatology offerings

Tuesday, September 4, 2012 12:36 PM

Montreal-based Valeant Pharmaceuticals International and Medicis Pharmaceutical of Scottsdale, Ariz., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the boards of both companies. The $44 price represents a 39% premium to Medicis' closing share price Friday, Aug. 31, the last trading day prior to the announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

More... »

Valeant Pharmaceuticals to acquire OraPharma

Friday, June 15, 2012 01:42 PM

Valeant Pharmaceuticals International has agreed to acquire OraPharma, a Horsham, Penn.-based specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. 

More... »

Valeant acquires Atlantis Pharma assets

Wednesday, April 18, 2012 02:59 PM

Valeant Pharmaceuticals International has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company in Mexico, for approximately $71 million.

More... »

Eisai partners with PharmaSwiss on chemo agent distribution

Monday, April 9, 2012 02:19 PM

Eisai Europe, the Tokyo-based subsidiary of Eisai, has entered into an agreement with PharmaSwiss, the Switzerland-based division of Valeant Pharmaceuticals International, to promote and distribute the Eisai's novel anticancer agent Halaven (eribulin mesylate) in a number of Central and Eastern European (CEE) countries.

More... »

Valeant moves global headquarters to Quebec

Wednesday, April 4, 2012 01:48 PM

Valeant Pharmaceuticals International is moving its global headquarters to the Montreal region and establishing an R&D center of excellence for consumer dermatologyin nearby Laval, Quebec.

More... »

ACT Oncology names Julia Amo as COO

Wednesday, March 28, 2012 12:02 PM

ACT Oncology, a niche oncology service provider, has appointed Julia Amo, MBA, PMP, as chief operating officer.

More... »

Valeant Pharmaceuticals to acquire Natur Produkt in Russia

Monday, March 26, 2012 10:58 AM

Valeant Pharmaceuticals International has signed a $180 million agreement to acquire Natur Produkt International, a specialty pharmaceutical company in St. Petersburg, Russia.

More... »

Valeant Pharma acquires 19.9% minority equity investment in Brazilian biotech

Tuesday, March 13, 2012 06:00 AM

Valeant Pharmaceuticals International has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia, a Brazilian research company focused on tissue regeneration. 

More... »

Valeant to acquire Eyetech

Wednesday, February 15, 2012 03:45 PM

Valeant Pharmaceuticals International has agreed to acquire Eyetech, a privately-owned ophthalmic biotechnology company, for an undisclosed upfront payment and potential future milestones.

More... »